After-Hours Stock Movers 09/27: (AAAP) (CHMA) (THO) Higher; (DXCM) (CMTL) (PIR) Lower (more...)

September 27, 2017 6:01 PM

Today's After-Hours Movers

DexCom (NASDAQ: DXCM) 14.8% LOWER; FDA approved Abbott's (NYSE: ABT) continuous glucose monitoring system for adults not requiring blood sample calibration.

Comtech Telecom (NASDAQ: CMTL) 13.2% LOWER; reported Q4 EPS of $0.31, $0.02 better than the analyst estimate of $0.29. Revenue for the quarter came in at $147.8 million versus the consensus estimate of $150.57 million.

Advanced Accelerator Applications (Nasdaq: AAAP) 10% HIGHER; Novartis (NYSE: NVS) is considering a deal for Advanced Accelerator Applications (Nasdaq: AAAP), according to Bloomberg, citing people familiar with the matter. Novartis approached AAA about a deal and held talks.

Pier 1 Imports (NYSE: PIR) 7.6% LOWER; reported Q2 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $407.6 million versus the consensus estimate of $406.82 million. Company comparable sales increased 1.8%. Sees FY18 comps (1%)-1%, EPS of $0.38-$0.48, versus the consensus of $0.47.

Chiasma, Inc. (NASDAQ: CHMA) 4% HIGHER; provided an update on both of its international Phase 3 clinical trials of its octreotide capsules product candidate, conditionally trade-named Mycapssa®, for the maintenance therapy of adult patients with acromegaly.

Thor Industries (NYSE: THO) 3.5% HIGHER; reported Q4 EPS of $2.26, $0.31 better than the analyst estimate of $1.95. Revenue for the quarter rose up 49.7% to $1.93 billion versus the consensus estimate of $1.84 million.

Abbott Laboratories (NYSE: ABT) 2% HIGHER; The U.S. Food and Drug Administration today approved the FreeStyle Libre Flash Glucose Monitoring System, the first continuous glucose monitoring system that can be used by adult patients to make diabetes treatment decisions without calibration using a blood sample from the fingertip (often referred to as a fingerstick).

Jabil Circuit (NYSE: JBL) 1% LOWER; reported Q4 EPS of $0.64, $0.02 better than the analyst estimate of $0.62. Revenue for the quarter came in at $5 billion versus the consensus estimate of $4.9 billion. Jabil sees Q1 revenue of $5.25 to $5.75 billion, versus the consensus of $5.38 billion. Sees Q1 EPS of $0.65-$0.91, versus the consensus of $0.83.

Categories

Special Reports

Next Articles